Molecular glue degraders: Lilly, AbbVie sign billion-dollar deals; BMS leads with three late-stage drugs

Data Compilation
#PharmaFlow

Pipeline Prospector Feb 2025: Bain buys Mitsubishi Tanabe for US$ 3.4 bn; Japan’s Ono gets FDA nod for rare joint tumor drug

Stock Recap
#PipelineProspector

Levonorgestrel

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

46 API Suppliers, 28 USDMF, 11 CEP/COS, 3 JDMF, 6 EU WC, 20 NDC API, 15 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

24 Drugs in Development

24 Drugs in Development

INTERMEDIATES

4 Intermediate Suppliers

4 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

296 FDF Dossiers, 136 FDA Orange Book, 80 Europe, 30 Canada, 4 Australia, 27 South Africa, 19 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL-28 - 0.03MG;0.3MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 0.02MG,0.15MG;0.025MG,0.15MG;0.03MG,0.15MG;0.01MG,N/A, SYSTEM;INTRAUTERINE - 52MG, TABLET;ORAL - 0.02MG;0.1MG, SYSTEM;INTRAUTERINE - 52MG, FILM, EXTENDED RELEASE;TRANSDERMAL - 0.045MG/24HR;0.015MG/24HR, TABLET;ORAL - 1.5MG

RELATED EXCIPIENT COMPANIES

5 SPI Pharma, 10 DKSH, 5 Faran Shimi Pharmaceutical, 4 Boai NKY Pharmaceuticals Ltd, 4 Gangwal Healthcare, 1 Nanjing Well Pharmaceutical, 4 ACG Worldwide, 3 Actylis, 1 Aeon Procare, 7 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 17 BASF, 11 Corel Pharma Chem, 5 DFE Pharma, 1 Doshion Polyscience, 1 Finar, 7 Gangwal Chemicals, 5 Ideal Cures Pvt Ltd, 3 Ingredion Pharma Solutions, 29 Kerry, 3 Kima Chemical, 6 Lonza Capsugel, 11 Microlex e.U, 2 Nomisma Healthcare, 2 Novo Excipients, 2 Pharmatrans-Sanaq, 5 Pluviaendo, 3 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 2 Qualicaps, 17 Roquette, 7 Seppic, 7 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 11 Sigachi Industries, 2 The Dow Chemical Company, 1 Ulanqab Kema New Material, 1 Valens Pharmachem, 3 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

65 Fillers, Diluents & Binders, 44 Coating Systems & Additives, 27 Controlled & Modified Release, 24 Thickeners and Stabilizers, 22 Disintegrants & Superdisintegrants, 22 Direct Compression, 20 Granulation, 13 Lubricants & Glidants, 13 Solubilizers, 11 Co-Processed Excipients, 10 Taste Masking, 9 Empty Capsules, 8 Film Formers & Plasticizers, 7 Topical, 6 Rheology Modifiers, 6 Chewable & Orodispersible Aids, 5 API Stability Enhancers, 4 Vegetarian Capsules, 4 Coloring Agents, 4 Emulsifying Agents, 3 Parenteral

DIGITAL CONTENT

1 Data Compilation #PharmaFlow, 79 News #PharmaBuzz

GLOBAL SALES INFORMATION

6 US Medicaid Prescriptions, 67 Regulatory FDF Prices, 14 Annual Reports

MARKET PLACE

8 APIs, 5 FDF Dossiers

PATENTS & EXCLUSIVITIES

20 US Patents, 2 US Exclusivities

REF. STANDARDS & IMPURITIES

5 EDQM, 3 USP, 1 JP, 8 Others

$ Xls download

Filters

Last Updated on PharmaCompass	Virtual Booth	Country	Registrant Name	MF Registration No.	Classification	Initial Date of Reg.	Latest Date of Reg.	Registrant's Address
28/03/2025	Formosa Laboratories	Taiwan	FORMOSA LABORATORIES, INC.	228MF10159	Levonorgestrel	2016-08-10	2017-02-22	36 Hoping Street, Louchu, Taoyuan 33842, Taiwan
28/03/2025	Industriale Chimica	Italy	INDUSTRIALE CHIMICA s. r. l.	221MF10183	Levonorgestrel	2009-08-13	2023-02-15	Via E. H. Grieg, 13, 21047 Saronno (Varese) ITALY

Levonorgestrel

Levonorgestrel

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

46 API Suppliers

28 USDMF

11 CEP/COS

3 JDMF

6 EU WC

20 NDC API

15 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

24 Drugs in Development

INTERMEDIATES

4 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

296 FDF Dossiers

136 FDA Orange Book

80 Europe

30 Canada

4 Australia

27 South Africa

19 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL-28 - 0.03MG;0.3MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - 0.02MG,0.15MG;0.025MG,0.15MG;0.03MG,0.15MG;0.01MG,N/A

SYSTEM;INTRAUTERINE - 52MG

TABLET;ORAL - 0.02MG;0.1MG

SYSTEM;INTRAUTERINE - 52MG

FILM, EXTENDED RELEASE;TRANSDERMAL - 0.045MG/24HR;0.015MG/24HR

TABLET;ORAL - 1.5MG

RELATED EXCIPIENT COMPANIES

5 SPI Pharma

10 DKSH

5 Faran Shimi Pharmaceutical

4 Boai NKY Pharmaceuticals Ltd

4 Gangwal Healthcare

1 Nanjing Well Pharmaceutical

4 ACG Worldwide

3 Actylis

1 Aeon Procare

7 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

17 BASF

11 Corel Pharma Chem

5 DFE Pharma

1 Doshion Polyscience

1 Finar

7 Gangwal Chemicals

5 Ideal Cures Pvt Ltd

3 Ingredion Pharma Solutions

29 Kerry

3 Kima Chemical

6 Lonza Capsugel

11 Microlex e.U

2 Nomisma Healthcare

2 Novo Excipients

2 Pharmatrans-Sanaq

5 Pluviaendo

3 Prachin Chemical

1 Qianhao Chemical (Hebei) Co., Ltd

2 Qualicaps

17 Roquette

7 Seppic

7 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

1 Shanghai Welltone Material Technology Co., Ltd

11 Sigachi Industries

2 The Dow Chemical Company

1 Ulanqab Kema New Material

1 Valens Pharmachem

3 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

65 Fillers, Diluents & Binders

44 Coating Systems & Additives

27 Controlled & Modified Release

24 Thickeners and Stabilizers

22 Disintegrants & Superdisintegrants

TABLET;ORAL-28 - 0.03MG;0.3MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons